ES2767070T3 - Utilización de cerebrolisina - Google Patents

Utilización de cerebrolisina Download PDF

Info

Publication number
ES2767070T3
ES2767070T3 ES17188180T ES17188180T ES2767070T3 ES 2767070 T3 ES2767070 T3 ES 2767070T3 ES 17188180 T ES17188180 T ES 17188180T ES 17188180 T ES17188180 T ES 17188180T ES 2767070 T3 ES2767070 T3 ES 2767070T3
Authority
ES
Spain
Prior art keywords
cerebrolysin
cadasil
use according
treated
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17188180T
Other languages
English (en)
Spanish (es)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ever Neuro Pharma GmbH
Original Assignee
Ever Neuro Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ever Neuro Pharma GmbH filed Critical Ever Neuro Pharma GmbH
Application granted granted Critical
Publication of ES2767070T3 publication Critical patent/ES2767070T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
ES17188180T 2017-08-28 2017-08-28 Utilización de cerebrolisina Active ES2767070T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17188180.8A EP3449931B1 (en) 2017-08-28 2017-08-28 Use of cerebrolysin

Publications (1)

Publication Number Publication Date
ES2767070T3 true ES2767070T3 (es) 2020-06-16

Family

ID=59745228

Family Applications (2)

Application Number Title Priority Date Filing Date
ES17188180T Active ES2767070T3 (es) 2017-08-28 2017-08-28 Utilización de cerebrolisina
ES18759322T Active ES2901508T3 (es) 2017-08-28 2018-08-28 Cerebrolisina para la utilización en el tratamiento de CADASIL

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES18759322T Active ES2901508T3 (es) 2017-08-28 2018-08-28 Cerebrolisina para la utilización en el tratamiento de CADASIL

Country Status (15)

Country Link
US (1) US12589118B2 (https=)
EP (2) EP3449931B1 (https=)
JP (1) JP7281450B2 (https=)
KR (1) KR102676274B1 (https=)
CN (1) CN111050780B (https=)
AU (1) AU2018326339A1 (https=)
CA (1) CA3073991A1 (https=)
EA (1) EA202090108A1 (https=)
ES (2) ES2767070T3 (https=)
HR (1) HRP20200031T1 (https=)
MX (1) MX2020002267A (https=)
PH (1) PH12020500376A1 (https=)
PL (2) PL3449931T3 (https=)
UA (1) UA129400C2 (https=)
WO (1) WO2019042983A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020198037A1 (en) * 2019-03-25 2020-10-01 The University Of Vermont Methods to promote cerebral blood flow in the brain
WO2022013236A1 (en) 2020-07-13 2022-01-20 Ever Neuro Pharma Gmbh Method for producing a mammalian brain protein hydrolysate
IL307903A (en) * 2021-06-02 2023-12-01 Regeneron Pharma Treatment of cerebrovascular disease with Notts homolog protein factors 3 neurogenic locus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69126563T2 (de) 1990-04-12 1998-02-05 Ebewe Arzneimittel Verwendung einer Mischung von Peptiden and Aminosäuren für die Prophylaxis oder Behandlung von Dementia
EP1857463A1 (en) * 2006-05-03 2007-11-21 Ebewe Pharma Ges.m.b.H. Nfg. KG Peptide having neuroprotective effects
EP2334287A4 (en) 2008-08-20 2013-12-25 Univ Texas MELT EXTRUSION OF MULTIPARTICLES WITH MODIFIED RELEASE

Also Published As

Publication number Publication date
PL3449931T3 (pl) 2020-06-01
KR20200045503A (ko) 2020-05-04
CN111050780B (zh) 2023-11-03
PL3675879T3 (pl) 2022-02-14
JP2020531568A (ja) 2020-11-05
UA129400C2 (uk) 2025-04-16
HRP20200031T1 (hr) 2020-03-20
KR102676274B1 (ko) 2024-06-18
ES2901508T3 (es) 2022-03-22
PH12020500376A1 (en) 2020-12-07
US20200376040A1 (en) 2020-12-03
JP7281450B2 (ja) 2023-05-25
CA3073991A1 (en) 2019-03-07
EP3675879B1 (en) 2021-09-15
AU2018326339A1 (en) 2020-03-05
EP3449931A1 (en) 2019-03-06
EP3675879A1 (en) 2020-07-08
CN111050780A (zh) 2020-04-21
EA202090108A1 (ru) 2020-03-31
EP3449931B1 (en) 2019-10-16
MX2020002267A (es) 2020-10-22
WO2019042983A1 (en) 2019-03-07
US12589118B2 (en) 2026-03-31

Similar Documents

Publication Publication Date Title
ES2968375T3 (es) Formulaciones de TPP1 y métodos para tratar la enfermedad CLN2
Silvio Taccone et al. Brain perfusion in sepsis
Lee et al. Fluoxetine inhibits transient global ischemia-induced hippocampal neuronal death and memory impairment by preventing blood–brain barrier disruption
ES2901508T3 (es) Cerebrolisina para la utilización en el tratamiento de CADASIL
ES2731266T3 (es) Terapia para hemorragia subaracnoidea e isquemia
JP2005523326A (ja) プロテインキナーゼｃのペプチドインヒビター
Walberer et al. RNase therapy assessed by magnetic resonance imaging reduces cerebral edema and infarction size in acute stroke
Broussalis et al. Current therapies in ischemic stroke. Part B. Future candidates in stroke therapy and experimental studies
Dhapola et al. Exploring Retinal Neurodegeneration in Alzheimer’s Disease: A Molecular and Cellular Perspective
Yuan et al. Ic100, a humanized therapeutic monoclonal anti-asc antibody alleviates oxygen-induced retinopathy in mice
CN103230581B (zh) 用于治疗创伤性脑损伤的组合物和方法
KR20070103009A (ko) 뇌혈류를 증가시키는 방법
Tolnai et al. Primary malignant melanomatosis of leptomeninges
EA040978B1 (ru) Применение церебролизина
Cordano et al. Inflammation in the anterior visual pathway in multiple sclerosis: what do the animal models teach us?
HK40026040B (en) Cerebrolysin for use in the treatment of cadasil
HRP20220370A1 (hr) Postupci liječenja cln2 bolesti kod pedijatrijskih subjekata
Ramos Pérez et al. Inflammation in the anterior visual pathway in multiple sclerosis: what do the animal models teach us?
Ma et al. Acupuncture improves white matter perfusion and white matter integrity in vascular dementia rats: an MRI-based imaging study
Zhao et al. Activation of PPARβ/δ by DHA induces VEGF-A expression to promote angiogenesis in the cerebral ischemia penumbra
Silva et al. Micro and Macro Morphologic Changes in Alzheimer's Disease
Coşkun et al. Neuroprotective effect of ACE inhibitors following cerebral ischemia in rats: histopathological evaluation
ES2946699A1 (es) Extracto de cerebro de cerdo y su uso en el tratamiento de enfermedades neurodegenerativas
Cordano et al. USA. 4Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa 16132, Italy. 5IRCCS Ospedale Policlinico San Martino, Genoa 16132, Italy. 6Department of Neurology, S. Paolo Hospital, Savona 17100, Italy.
Agadjanyan et al. P4–329: Different susceptibilities of oligomeric and fibrillar forms of β–amyloid to antibodies specific to N–terminus of this peptide